Syros Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Syros Pharmaceuticals, Inc.‘s stocks are currently a part of 44 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 9.27M shares of Syros Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 160.77% or 5.71M shares more. As for the holding position changes, 4.55% (2) of current hedge fund investors increased the number of shares held, and 120.45% (53) closed the holdings completely. 42 hedge funds are new holders of Syros Pharmaceuticals, Inc. stock in Q3 2022, it is 95.45% of total holders.
Hedge funds holding Syros Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 68 |
|---|---|
| Q1 2018 | 56 |
| Q2 2018 | 76 |
| Q3 2018 | 76 |
| Q4 2018 | 67 |
| Q1 2019 | 64 |
| Q2 2019 | 65 |
| Q3 2019 | 61 |
| Q4 2019 | 70 |
| Q1 2020 | 64 |
| Q2 2020 | 79 |
| Q3 2020 | 92 |
| Q4 2020 | 100 |
| Q1 2021 | 103 |
| Q2 2021 | 99 |
| Q3 2021 | 96 |
| Q4 2021 | 86 |
| Q1 2022 | 87 |
| Q2 2022 | 61 |
| Q3 2022 | 44 |
Hedge funds changes in Syros Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 18 | 25 | 13 | 18 | -6 |
|---|---|---|---|---|---|
| Q1 2018 | 7 | 27 | 10 | 19 | -7 |
| Q2 2018 | 26 | 31 | 10 | 6 | 3 |
| Q3 2018 | 9 | 25 | 25 | 9 | 8 |
| Q4 2018 | 8 | 25 | 21 | 17 | -4 |
| Q1 2019 | 7 | 24 | 22 | 10 | 1 |
| Q2 2019 | 12 | 34 | 14 | 9 | -4 |
| Q3 2019 | 7 | 24 | 16 | 11 | 3 |
| Q4 2019 | 18 | 30 | 14 | 9 | -1 |
| Q1 2020 | 12 | 22 | 22 | 17 | -9 |
| Q2 2020 | 20 | 36 | 16 | 5 | 2 |
| Q3 2020 | 21 | 21 | 37 | 8 | 5 |
| Q4 2020 | 25 | 35 | 29 | 16 | -5 |
| Q1 2021 | 16 | 44 | 28 | 13 | 2 |
| Q2 2021 | 19 | 46 | 20 | 23 | -9 |
| Q3 2021 | 15 | 28 | 35 | 17 | 1 |
| Q4 2021 | 11 | 30 | 31 | 22 | -8 |
| Q1 2022 | 14 | 26 | 30 | 13 | 4 |
| Q2 2022 | 12 | 16 | 22 | 36 | -25 |
| Q3 2022 | 42 | 2 | 0 | 53 | -53 |
Hedge funds changes in Syros Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 28,000 | 267,000 |
|---|---|---|
| Q1 2018 | 332,000 | 111,000 |
| Q2 2018 | 147,000 | 270,000 |
| Q3 2018 | 464,000 | 279,000 |
| Q4 2018 | 85,000 | 0 |
| Q1 2019 | 247,000 | 0 |
| Q2 2019 | 931,000 | 3,000 |
| Q3 2019 | 1,561,000 | 13,000 |
| Q4 2019 | 956,000 | 0 |
| Q1 2020 | 611,000 | 0 |
| Q2 2020 | 941,000 | 0 |
| Q3 2020 | 11,000 | 24,000 |
| Q4 2020 | 1,698,000 | 1,298,000 |
| Q1 2021 | 1,323,000 | 3,173,000 |
| Q2 2021 | 893,000 | 2,662,000 |
| Q3 2021 | 224,000 | 1,547,000 |
| Q4 2021 | 85,000 | 249,000 |
| Q1 2022 | 33,000 | 14,000 |
| Q2 2022 | 2,000 | 10,000 |
| Q3 2022 | 1,978,000 | 94,000 |